home / stock / alpmf / alpmf short
Short Information | Astellas Pharma Inc (OTCMKTS:ALPMF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 15,449 |
Total Actual Volume | 76,187 |
Short Trends | |
---|---|
Cover Days | 7 |
Short Days | 11 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 772 |
Average Short Percentage | 57.43% |
Is there a ALPMF Short Squeeze or Breakout about to happen?
See the ALPMF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
05-03-2024 | $0 | $9.521 | $0 | $0 | 60 | 60 | 100% |
04-25-2024 | $9.6 | $9.8414 | $9.8414 | $9.6 | 22,820 | 2,500 | 10.96% |
04-16-2024 | $9.13 | $9.594 | $9.594 | $9.13 | 2,166 | 250 | 11.54% |
04-12-2024 | $9.59 | $9.48 | $9.59 | $9.48 | 1,720 | 1,200 | 69.77% |
03-27-2024 | $10.83 | $11.165 | $11.165 | $10.83 | 900 | 500 | 55.56% |
03-21-2024 | $0 | $11.09 | $0 | $0 | 50 | 50 | 100% |
03-20-2024 | $0 | $11.09 | $0 | $0 | 90 | 90 | 100% |
03-19-2024 | $11.26 | $11.09 | $11.26 | $10.58 | 4,544 | 780 | 17.17% |
03-18-2024 | $11.31 | $11.31 | $11.31 | $11.31 | 925 | 925 | 100% |
03-13-2024 | $10.74 | $10.74 | $10.74 | $10.74 | 200 | 200 | 100% |
03-08-2024 | $11.33 | $11 | $11.33 | $11 | 14,800 | 3,500 | 23.65% |
03-04-2024 | $11.62 | $11.62 | $11.62 | $11.62 | 300 | 300 | 100% |
02-26-2024 | $0 | $11.04 | $0 | $0 | 81 | 4 | 4.94% |
02-20-2024 | $11.04 | $11.04 | $11.04 | $11.04 | 1,833 | 1 | 0.05% |
02-09-2024 | $10.85 | $11.271 | $11.271 | $10.85 | 16,346 | 450 | 2.75% |
02-06-2024 | $11.12 | $11.12 | $11.12 | $11.12 | 2,713 | 1,000 | 36.86% |
02-05-2024 | $12 | $11.1 | $12 | $10.98 | 2,100 | 1,600 | 76.19% |
01-31-2024 | $12.051 | $12.051 | $12.051 | $12.051 | 224 | 224 | 100% |
01-30-2024 | $11.55 | $11.55 | $11.55 | $11.55 | 200 | 200 | 100% |
01-29-2024 | $11.3999 | $11.35 | $11.4 | $11.35 | 4,115 | 1,615 | 39.25% |
News, Short Squeeze, Breakout and More Instantly...
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...
Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...
Astellas Pharma Inc (OTC: ALPMY) (OTC: ALPMF) has elected not to exercise its option to obtain an exclusive license to TSHA-120 unde...